Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04956640 · ClinicalTrials.gov registry record · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
A Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 540
- Enrollment target
- 20
- Study locations
NCT04956640 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 540 participants, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (69% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT04956640, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 540 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Cetuximab
- DRUG LY3537982
Study Locations (20)
New York
- NYU Langone Health- Long Island - Mineola
- NYU Langone - New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- The University of North Carolina at Chapel Hill - Chapel Hill
- Novant Health Cancer Institute - Elizabeth - Charlotte
- Novant Health Cancer Institute - Forsyth - Winston-Salem
California
- USC Norris Cancer Hospital - Los Angeles
- Chao Family Comprehensive Cancer Ctr. - Orange
Florida
- AdventHealth Orlando - Orlando
- Florida Cancer Specialists - Sarasota
Indiana
- Indiana Univ Melvin & Bren Simon Cancer Center - Indianapolis
- Community Health Network - Indianapolis
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- UPMC Hillman Cancer Center - Pittsburgh
Alabama
- University of Alabama at Birmingham - Birmingham
Connecticut
- Yale-New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2021-07-19 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04956640
The ClinicalTrials.gov registry entry for NCT04956640 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 540 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (69% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT04956640 reports 20 study locations spanning 12 distinct geographic areas - top geographies include New York, North Carolina, California.
Frequently Asked Questions
What is clinical trial NCT04956640 about?
NCT04956640 is a clinical study titled "Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)". The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had ca...
What is the current status of trial NCT04956640?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 540 participants. The study started on 2021-07-19. Estimated completion is 2027-04.
What conditions does trial NCT04956640 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Colorectal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms.
What interventions are being tested in trial NCT04956640?
The interventions under investigation include: Pembrolizumab (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Cetuximab (DRUG), LY3537982 (DRUG).
Who is sponsoring clinical trial NCT04956640?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04956640 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.